Chief Executve Officer & Founder

​

                     Sridhar Vempati

 

Harvard University Postdoc Leukemia Research, BD Ironwood and Rafael Pharma​

​

• PhD in Human Biology from Ludwig-Maximilians University                                           

• MBA from Boston University                              

• Postdoctoral research at Harvard University in leukemia and the target of AO-001                             

• Authored several articles in oncology in leading publications                                          

• Biotechnology industry analyst experience at Jeffries LLC 

​

​

Chairman & CIO, Founder

​

Edward Painter, MBA

​

Research and Biotech focused capital markets with Goldman Sachs, Credit Suisse & UBS​​

​

• MBA from University of Illinois at Urbana-Champaign Chairman & CIO, Founder

​

• Former VP at UBS, Oppenheimer & Co., Credit Suisse, and Kidder Peabody

​

• Former analyst at Goldman Sachs and Salomon Brothers

​

• 30 years of experience in finance

​

• Has worked extensively with biotech companies in financing and investment decisions

Chief Scientific Officer

​

Chaemin Lim, Phd

​

Medicinal and Computational Chemist. Seoul National University, University of Pittsburgh, UPCDC

​

• PhD in Synthetic and Medicinal Chemistry from the Seoul National University

​

• Postdoctoral research in Chemistry from the University of Pittsburgh

​

• Extensive research experience in synthetic organic chemistry and drug discovery covering multiple therapeutic areas

​

• Co-authored 20 SCI papers and 9 patent applications as a co-inventor

​

• Has contributed to drug discovery and development projects ranging from early development stages through to preclinical trials particularly using in silico drug design tools

Public Relations                 

​

                   Robbin Frnka

​

More than 20 years of experience in the oncology clinical research industry in both the academic and community settings. Her experience includes building research programs and networks in both community and hospital settings to ensure compliance with all regulated guidelines and to streamline operational processes and efficiencies to ensure the safe delivery of investigational drugs into the outpatient chemotherapy setting. I have extensive experience in direct industry, cooperative group and investigator initiated clinical trials in all phases of the drug development process.